血管靶向药物治疗血管肉瘤的1个病例报告和文献复习

Case report and literature review of vascular targeting agents in the treatment of 1 angiosarcoma case

血管肉瘤是一种罕见的有侵袭性的起源于血管内皮的肿瘤,预后极差。无法手术的患者治疗方法非常有限,而且没有治疗标准。贝伐珠单抗是一个抗血管内皮生长因子的血管生成抑制剂,是重组人源化的单克隆抗体,可以作为血管肉瘤治疗的一种有前景的选择。这是一个采用贝伐珠单抗联合化疗药物治疗血管肉瘤的病例报道和文献回顾,患者通过治疗得到了短期的缓解获益并提高了生活质量。

Angiosarcoma is a rare and aggressive vascular neoplasm with very poor prognosis. There is very limited choice of treatment methods for patients who cannot undergo surgical treatment, and no treatment standard exists. Bevacizumab, as an angiogenesis inhibitor for anti vascular endothelial growth factor and a recombined humanized monoclonal antibody, can be treated as a promising choice for treating angiosarcoma. This paper revived the case report and literature review of combined application of bevacizumab and chemotherapy in the treatment of angiosarcoma. This treatment provided short-term effect for patients, whose life quality was also improved.